PremiumThe FlyKronos Bio provides update on review of strategic alternatives Piper downgrades Kronos Bio on istisociclib discontinuation Kronos Bio downgraded to Hold from Buy at TD Cowen PremiumPre-EarningsKRON Earnings Report this Week: Is It a Buy, Ahead of Earnings? Kronos Bio announces preclinical data from p300 KAT inhibitor program Kronos Bio to present data from p300 KAT inhibitor program PremiumThe FlyKronos Bio:1st patient dosed in expansion cohort with KB-0742 for HGSOC Kronos Bio appoints Deborah Knobelman as COO, CFO Kronos Bio reports Q1 EPS (50c), consensus (42c) 
